Status:
COMPLETED
Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)
Lead Sponsor:
Hospital General de Mexico
Conditions:
Irritable Bowel Syndrome With Diarrhea
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Background: The combination of Lactobacillus fermentum and Lactobacillus delbrueckii (Lactobacillus LB) has proven to be effective and safe for the treatment of acute diarrhea in children. Also, a cli...
Detailed Description
Background: The combination of Lactobacillus fermentum and Lactobacillus delbrueckii (Lactobacillus LB) has proven to be effective and safe for the treatment of acute diarrhea in children. Also, a cli...
Eligibility Criteria
Inclusion
- Patients meeting Rome IV criteria for IBS-D, without specific medical treatment for the last 4 weeks prior to inclusion in this study.
Exclusion
- Presence of any chronic organic disease, consumption of any medication, patients with alterations in blood cell count, erythrocyte sedimentation rate, thyroid function tests, liver function tests, blood chemistry, anti-endomysial or anti-transglutaminase antibodies, positive test for presence of blood in stools, fecal calprotectin \> 50mcg/g. Also, those who do not sign informed consent.
Key Trial Info
Start Date :
January 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2023
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT04053790
Start Date
January 15 2019
End Date
January 29 2023
Last Update
March 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General de Mexico
Mexico City, Choose Any State/Province, Mexico, 06726